Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (OCGN) will present its modifier gene therapy platform at upcoming scientific conferences in Vienna and New Orleans.
The schedule includes a company overview at Euretina Innovation Spotlight on September 30, 2026, and presentations at the 26th Euretina Congress on October 1–4 covering geographic atrophy and Stargardt disease. At the American Academy of Ophthalmology Annual Meeting on October 9–12, presentations will cover twelve-month safety and efficacy results from the Phase 2 ArMaDa trial of OCU410, the Phase 1 GARDian1 trial of OCU410ST in Stargardt disease, and three-year visual function results for OCU400 in retinitis pigmentosa.
Ocugen (OCGN) will participate in two October 2026 investor and industry conferences featuring Chairman and CEO Shankar Musunuri.
Musunuri will moderate a financing panel at H.C. Wainwright’s Biotech on Tap in Munich on October 1. He will also participate in a panel on cell and gene therapy approval and commercialization at Cell & Gene Meeting on the Mesa in Phoenix on October 6.
Ocugen (OCGN) announced on September 25, 2026, that OCU400 received provisional approval and priority designation in The Bahamas.
OCU400 is an investigational gene therapy for retinitis pigmentosa. Ocugen plans to supply it through an expanded access program and aims to treat the first patient within 90 days following full approval by the Longevity and Regenerative Therapies Board. The therapy is in Phase 3 testing. Ocugen expects topline data in the first quarter of 2027 and plans to submit a Biologics License Application in the second quarter of 2027.
Ocugen (NASDAQ: OCGN) reported dosing the first patient in ArMaDa3, its global, single Phase 3 registrational trial of OCU410, a one-time subretinal modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration. The 237‑patient, randomized 2:1 study compares OCU410 to an untreated control, using GA lesion growth rate by fundus autofluorescence as the primary endpoint and functional vision and ellipsoid zone preservation as key secondary endpoints.
According to Ocugen, the FDA granted RMAT designation to OCU410 on July 29, 2026, and aligned with a single, adequate and well‑controlled Phase 3 to support a planned BLA filing in 2028. Phase 2 12‑month data showed a statistically significant 31% reduction in GA lesion growth at the medium dose versus control and no OCU410‑related serious adverse events or adverse events of special interest.
Ocugen (NASDAQ: OCGN) will highlight its modifier gene therapy platform and clinical progress at three events in September 2026. The company is participating in the Citi 2026 Biopharma Back to School Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, both as fireside chats featuring Chairman and CEO Dr. Shankar Musunuri. On September 24, Ocugen will present 12‑month randomized Phase 2 ArMaDa results for subretinal OCU410 gene therapy in geographic atrophy at The Retina Society 59th Annual Scientific Meeting, presented by Dr. Raj K. Maturi. Webcasts of the Citi and H.C. Wainwright sessions will be accessible via the Investors section of Ocugen’s website, with replays available for 30 days.
Ocugen (NASDAQ: OCGN) reported second quarter 2026 results and a broad business update. FDA cleared the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy, based on 12‑month Phase 2 data showing a statistically significant 31% reduction in lesion growth at the planned Phase 3 dose, and granted RMAT designation, with BLA/MAA filings targeted for 2028.
Enrollment was completed in pivotal trials of OCU400 for retinitis pigmentosa (N=140) and OCU410ST for Stargardt disease (N=63), with topline data expected in 1Q and 2Q 2027, respectively. Ocugen signed a binding term sheet with Roots Pharmaceutical and Al‑Dhow International Holding for an exclusive OCU400 license in MENA, including up to $255 million in sales milestones and a 22% royalty on net sales.
The company closed a $130.0 million 6.75% convertible senior notes offering (net proceeds ~$112.5 million), using ~$32.7 million to fully retire higher‑cost Avenue Capital debt, and extending its cash runway into 2028. As of June 30, 2026, cash and restricted cash were $100.4 million, revenue was $1.5 million, operating expenses were $17.9 million, and net loss was $24.9 million, or $0.07 per share.
Ocugen (NASDAQ: OCGN) will participate in two August 2026 investor events focused on its modifier gene therapy platform for blindness diseases. The company will join a panel at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4 in Lenox, MA, and host a fireside chat at the Canaccord 46th Annual Growth Conference on August 11 in Boston, MA. A live webcast and 30-day replay of the Canaccord session will be available via the Investors section of Ocugen’s website.
Ocugen (NASDAQ: OCGN) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational gene therapy OCU410 for treating geographic atrophy (GA) secondary to dry age-related macular degeneration.
According to Ocugen, the RMAT designation, based on Phase 2 data showing clinically meaningful efficacy and a favorable safety profile with no serious drug-related adverse events reported, may enable an expedited regulatory path. The company recently aligned with the FDA on the design of a Phase 3 registrational trial, which it expects to initiate in the third quarter of 2026, and anticipates filing a Biologics License Application (BLA) in 2028.
Ocugen (NASDAQ: OCGN) announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 6, 2026 to discuss its second quarter 2026 financial results and provide a business update. A pre-market earnings announcement will be issued the same day.
According to Ocugen, U.S. participants can dial (800) 715-9871 and international participants can dial (646) 307-1963, using Conference ID: 2222566. A live and archived webcast, as well as a replay of the call, will be available in the events section of the Ocugen investor website.
Ocugen (NASDAQ: OCGN) signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, a modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa (MENA) region.
According to Ocugen, the anticipated license agreement would provide up to $4 million in upfront and near-term development milestone payments, cumulative sales milestones up to $255 million, and a 22% royalty on net sales generated by its partner. Ocugen would also manufacture commercial supply of OCU400 under a related supply agreement. The company continues to advance OCU400 in its Phase 3 liMeliGhT trial, with topline data expected in 1Q 2027 followed by a planned BLA submission. Execution of the definitive agreement is expected within 90 days.